Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H46N2O |
| Molecular Weight | 402.6562 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C
InChI
InChIKey=GMNAPBAUIVITMI-ABNIRSKTSA-N
InChI=1S/C26H46N2O/c1-16(27-6)21-17(29)14-24(5)19-9-8-18-22(2,3)20(28-7)10-11-25(18)15-26(19,25)13-12-23(21,24)4/h16-21,27-29H,8-15H2,1-7H3/t16-,17+,18-,19-,20-,21-,23+,24-,25+,26-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24758922
https://www.ncbi.nlm.nih.gov/pubmed/17555743
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24758922
https://www.ncbi.nlm.nih.gov/pubmed/17555743
Cyclovirobuxine D (CVB-D) is an active compound extracted from Buxus microphylla, which has been used of cardiac insufficiency and arrhythmias in China. The antiarrhythmic and proarrhythmic potential of this drug might be concerned with prolongation of action potential duration and QT interval. Human-ether-a-go-go-related gene (HERG) has an important role in the repolarization of the cardiac action potential. CVB-D inhibits HERG encoded potassium channels and this action might be a molecular mechanism for the previously reported APD prolongation and QT interval prolongation with this drug. Currently pharmacological studies on CVB-D have been conducted extensively for treatment of cancers. However, whether and how CVB-D affects other cellular processes and the tumorigenesis pathway of cancer cells is still largely unknown.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL240 |
19.7 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16765010 |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CYCLOVIROBUXINE D plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
47.22 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16765010 |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CYCLOVIROBUXINE D plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16765010 |
2 mg single, intravenous dose: 2 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CYCLOVIROBUXINE D plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
To study the potential role(s) of Cyclovirobuxine D (CVB-D) in gastric cancer cells, firstly tested the cell viability of MGC-803 and MKN 28 cells after CVB-D treatment. After incubation with 0, 30, 60, 120 and 240 umol/L CVB-D for 24, 48 and 72 h, the viabilities of MGC-803 and MKN28 cells were measured using the MTT assay. CVB-D reduced cell viability and colony formation ability of MGC-803 and MKN28 cells in a time- and concentration-dependent manner. Flow cytometry showed that cell cycle of CVB-D treated cells was arrested at the S-phase. CVB-D also induced apoptosis in MGC-803 and MKN28 cells, especially early stage apoptosis. Furthermore, mitochondria membrane potential (Δψm) was reduced and apoptosis-related proteins, cleaved Caspase-3 and Bax/Bcl-2, were up-regulated in CVB-D-treated MGC-803 and MKN28 cells. Taken together, our studies found that CVB-D plays important roles in inhibition of gastric tumorigenesis via arresting cell cycle and inducing mitochondria-mediated apoptosis, suggesting the potential application of CVB-D in gastric cancer therapy.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
260439
Created by
admin on Mon Mar 31 21:10:00 GMT 2025 , Edited by admin on Mon Mar 31 21:10:00 GMT 2025
|
PRIMARY | |||
|
860-79-7
Created by
admin on Mon Mar 31 21:10:00 GMT 2025 , Edited by admin on Mon Mar 31 21:10:00 GMT 2025
|
PRIMARY | |||
|
DTXSID801316983
Created by
admin on Mon Mar 31 21:10:00 GMT 2025 , Edited by admin on Mon Mar 31 21:10:00 GMT 2025
|
PRIMARY | |||
|
91722
Created by
admin on Mon Mar 31 21:10:00 GMT 2025 , Edited by admin on Mon Mar 31 21:10:00 GMT 2025
|
PRIMARY | |||
|
51GY352868
Created by
admin on Mon Mar 31 21:10:00 GMT 2025 , Edited by admin on Mon Mar 31 21:10:00 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
